Maihemuti Yakufu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maihemuti Yakufu has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Ainikaer Abulaiti
Department of Sports Medicine, Sixth Affiliated Hospital of Xinjiang Medical University, Urumqi, PR China
7 shared publications- Guohua Li
Orthopaedic Research Center, Sixth Affiliated Hospital of Xinjiang Medical University, Urumqi, 830002, PR China
7 shared publications Deyu Li
Orthopaedic Research Center, Sixth Affiliated Hospital of Xinjiang Medical University, Orthopedic Hospital of Xinjiang Uygur Autonomous Region, Urumqi, People’s Republic of China
6 shared publicationsJiashun Li
Orthopaedic Research Center, Sixth Affiliated Hospital of Xinjiang Medical University, Orthopedic Hospital of Xinjiang Uygur Autonomous Region, Urumqi, People’s Republic of China
6 shared publications- Li Shu
Department of Sports Medicine, Sixth Affiliated Hospital of Xinjiang Medical University, Urumqi, PR China
6 shared publications Yuxiang Zhang
Department of Sports Medicine, Sixth Affiliated Hospital of Xinjiang Medical University, Urumqi, PR China
6 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by Springer Nature in Discover Nano
- Vol. 21 (1) , 578
Nanomaterial applications and emerging trends in osteoarthritis from 2005 to 2025
- 30 October 2026
- Published by Springer Nature in Discover Nano
- Vol. 21 (1) , 578
Open AccessNanomaterial applications and emerging trends in osteoarthritis from 2005 to 2025
- Open Access
- 28 September 2026
- Published by Springer Nature in Langenbeck's Archives of Surgery
Comparison of efficacy and safety between unilateral biportal endoscopy and percutaneous endoscopic surgery for cervical spondylotic radiculopathy based on current evidence: a systematic review and meta-analysis
- 28 September 2026
- Published by Springer Nature in Langenbeck's Archives of Surgery
Open AccessComparison of efficacy and safety between unilateral biportal endoscopy and percutaneous endoscopic surgery for cervical spondylotic radiculopathy based on current evidence: a systematic review and meta-analysis
- Open Access
- 21 September 2026
- Published by Springer Nature in BMC Medical Imaging
WEM-Mamba: a Wavelet-Enhanced MedMamba framework for rotator cuff tear classification in X-ray images
- 21 September 2026
- Published by Springer Nature in BMC Medical Imaging
Open AccessWEM-Mamba: a Wavelet-Enhanced MedMamba framework for rotator cuff tear classification in X-ray images
- Open Access
- 28 June 2026
- Published by Elsevier in Ageing Research Reviews
- Vol. 120, 103221
From lifespan extension to hallmark-informed gerotherapeutic prioritization: A bibliometric-guided, strategy-oriented review of anti-aging drug research
- 28 June 2026
- Published by Elsevier in Ageing Research Reviews
- Vol. 120, 103221
Open AccessFrom lifespan extension to hallmark-informed gerotherapeutic prioritization: A bibliometric-guided, strategy-oriented review of anti-aging drug research
- Open Access
- 20 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1811816
Efficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies
Objective: BCMA- or GPRC5D-directed CD3 bispecific antibodies are important T-cell–redirecting therapies for relapsed/refractory multiple myeloma (RRMM). We evaluated their efficacy, safety, and certainty of evidence. Methods: We searched the Cochrane Library, Embase, PubMed, Scopus, and Web of Science from inception to February 5, 2026. Prospective clinical trials and real-world studies of BCMA×CD3 or GPRC5D×CD3 bispecific antibodies in RRMM with extractable efficacy and safety data were included. Main efficacy outcomes were progression-free survival (PFS), stringent complete response (sCR), complete response (CR), complete response or better (≥CR), very good partial response or better (≥VGPR), and overall response rate (ORR). Safety outcomes included cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infection, neutropenia, anemia, and thrombocytopenia. Single-arm proportional meta-analyses, sensitivity analyses, meta-regression, and subgroup analyses were performed using STATA/MP 18.0. Methodological quality and evidence certainty were assessed using MINORS and GRADE, respectively. Results: Fifteen studies, including 17 independently extractable cohorts and 1,900 patients, were analyzed. The pooled PFS was 8.76 months (95% CI, 6.82–11.13). The pooled rates of sCR, CR, ≥CR, ≥VGPR, and ORR were 28.7%, 18.1%, 38.2%, 51.0%, and 65.9%, respectively. The pooled incidences of CRS, ICANS, infection, grade ≥3 infection, neutropenia, and grade ≥3 neutropenia were 67.5%, 9.7%, 60.3%, 38.3%, 54.7%, and 42.6%, respectively. MINORS showed moderate-to-high methodological quality. GRADE showed low-to-very low certainty of evidence. Conclusion: BCMA- or GPRC5D-directed CD3 bispecific antibodies showed clinically meaningful antitumor activity in RRMM. However, current evidence is mainly from single-arm trials and retrospective real-world studies, and certainty of evidence remains low to very low. These findings should be interpreted cautiously, with particular attention to infection and neutropenia in clinical practice.
- 20 May 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1811816
Open AccessEfficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies
Objective: BCMA- or GPRC5D-directed CD3 bispecific antibodies are important T-cell–redirecting therapies for relapsed/refractory multiple myeloma (RRMM). We evaluated their efficacy, safety, and certainty of evidence. Methods: We searched the Cochrane Library, Embase, PubMed, Scopus, and Web of Science from inception to February 5, 2026. Prospective clinical trials and real-world studies of BCMA×CD3 or GPRC5D×CD3 bispecific antibodies in RRMM with extractable efficacy and safety data were included. Main efficacy outcomes were progression-free survival (PFS), stringent complete response (sCR), complete response (CR), complete response or better (≥CR), very good partial response or better (≥VGPR), and overall response rate (ORR). Safety outcomes included cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), infection, neutropenia, anemia, and thrombocytopenia. Single-arm proportional meta-analyses, sensitivity analyses, meta-regression, and subgroup analyses were performed using STATA/MP 18.0. Methodological quality and evidence certainty were assessed using MINORS and GRADE, respectively. Results: Fifteen studies, including 17 independently extractable cohorts and 1,900 patients, were analyzed. The pooled PFS was 8.76 months (95% CI, 6.82–11.13). The pooled rates of sCR, CR, ≥CR, ≥VGPR, and ORR were 28.7%, 18.1%, 38.2%, 51.0%, and 65.9%, respectively. The pooled incidences of CRS, ICANS, infection, grade ≥3 infection, neutropenia, and grade ≥3 neutropenia were 67.5%, 9.7%, 60.3%, 38.3%, 54.7%, and 42.6%, respectively. MINORS showed moderate-to-high methodological quality. GRADE showed low-to-very low certainty of evidence. Conclusion: BCMA- or GPRC5D-directed CD3 bispecific antibodies showed clinically meaningful antitumor activity in RRMM. However, current evidence is mainly from single-arm trials and retrospective real-world studies, and certainty of evidence remains low to very low. These findings should be interpreted cautiously, with particular attention to infection and neutropenia in clinical practice.
- 24 March 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 14 (15) , 4498-4524
Chondroitin sulfate in osteoarthritis treatment: a twenty-year bibliometric analysis and comprehensive review
Analysis of 2004 articles outlines chondroitin sulfate's evolving trajectory in osteoarthritis treatment across three phases: pharmacological treatment, tissue engineering and biomaterials, and precise drug delivery.
- 24 March 2026
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 14 (15) , 4498-4524
Chondroitin sulfate in osteoarthritis treatment: a twenty-year bibliometric analysis and comprehensive review
Analysis of 2004 articles outlines chondroitin sulfate's evolving trajectory in osteoarthritis treatment across three phases: pharmacological treatment, tissue engineering and biomaterials, and precise drug delivery.
- 11 March 2026
- Published by Elsevier in Journal of Orthopaedics
- Vol. 76, 56-67
Research trends and knowledge map construction of the mechanism of action between growth factors and osteoarthritis based on bibliometrics
- 11 March 2026
- Published by Elsevier in Journal of Orthopaedics
- Vol. 76, 56-67
Research trends and knowledge map construction of the mechanism of action between growth factors and osteoarthritis based on bibliometrics
- Open Access
- 8 January 2026
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 12, 1715571
Risk factors for periprosthetic joint infection following primary total knee arthroplasty: a systematic review and meta-analysis
Objective: Periprosthetic joint infection (PJI) represents a severe and devastating complication following primary total knee arthroplasty (TKA), leading to higher morbidity and implant failure. However, existing evidence regarding its risk factors remains inconsistent. Method: PubMed, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Chinese Journal Database, and the Chinese Biomedical Literature Service System (SinoMed) were searched for primary studies from the database inception to August 2025. Data were managed with EndNote X9 software, meta-analyses were performed using Review Manager 5.4, infection risk was analyzed using STATA 18, and the comprehensive incidence rate of PJI was analyzed using R 4.5.1. Results: A total of 1,569 studies were identified, of which 20 were included in this systematic review. The meta-analysis including 20 studies analyzed eight risk factors: longer operation time (OR = 9.10, 95% CI: 7.66–10.80), obesity (OR = 13.95, 95% CI: 12.06–16.14), male gender (OR = 2.67, 95% CI: 1.80–3.95), diabetes (OR = 2.98, 95% CI: 2.27–3.92), longer hospital stay (OR = 1.73, 95% CI: 1.38–2.16), use of immunosuppressants (OR = 5.76, 95% CI: 2.77–11.98), hypoalbuminemia (OR = 6.24, 95% CI: 4.00–9.73), and underlying systemic inflammatory disease (OR = 3.47, 95% CI: 1.92–6.27). All identified risk factors were associated with an increased risk of developing PJI after primary TKA. Conclusion: The meta-analysis confirmed that longer operative time, obesity, male gender, diabetes, longer hospital stay, use of immunosuppressants, hypoalbuminemia, and underlying systemic inflammatory disease are risk factors for PJI after primary TKA. This systematic review and meta-analysis provide Level II evidence (according to the Oxford Centre for Evidence-Based Medicine criteria) for the identified risk factors.
- 8 January 2026
- Published by Frontiers Media SA in Frontiers in Surgery
- Vol. 12, 1715571
Open AccessRisk factors for periprosthetic joint infection following primary total knee arthroplasty: a systematic review and meta-analysis
Objective: Periprosthetic joint infection (PJI) represents a severe and devastating complication following primary total knee arthroplasty (TKA), leading to higher morbidity and implant failure. However, existing evidence regarding its risk factors remains inconsistent. Method: PubMed, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Chinese Journal Database, and the Chinese Biomedical Literature Service System (SinoMed) were searched for primary studies from the database inception to August 2025. Data were managed with EndNote X9 software, meta-analyses were performed using Review Manager 5.4, infection risk was analyzed using STATA 18, and the comprehensive incidence rate of PJI was analyzed using R 4.5.1. Results: A total of 1,569 studies were identified, of which 20 were included in this systematic review. The meta-analysis including 20 studies analyzed eight risk factors: longer operation time (OR = 9.10, 95% CI: 7.66–10.80), obesity (OR = 13.95, 95% CI: 12.06–16.14), male gender (OR = 2.67, 95% CI: 1.80–3.95), diabetes (OR = 2.98, 95% CI: 2.27–3.92), longer hospital stay (OR = 1.73, 95% CI: 1.38–2.16), use of immunosuppressants (OR = 5.76, 95% CI: 2.77–11.98), hypoalbuminemia (OR = 6.24, 95% CI: 4.00–9.73), and underlying systemic inflammatory disease (OR = 3.47, 95% CI: 1.92–6.27). All identified risk factors were associated with an increased risk of developing PJI after primary TKA. Conclusion: The meta-analysis confirmed that longer operative time, obesity, male gender, diabetes, longer hospital stay, use of immunosuppressants, hypoalbuminemia, and underlying systemic inflammatory disease are risk factors for PJI after primary TKA. This systematic review and meta-analysis provide Level II evidence (according to the Oxford Centre for Evidence-Based Medicine criteria) for the identified risk factors.
- 14 November 2025
- Published by Elsevier in Journal of Orthopaedics
- Vol. 72, 208-219
Exploring the prospects of hydrogel in enhancing cartilage repair: Bibliometric and visual analysis (2005–2024)
- 14 November 2025
- Published by Elsevier in Journal of Orthopaedics
- Vol. 72, 208-219
Exploring the prospects of hydrogel in enhancing cartilage repair: Bibliometric and visual analysis (2005–2024)
- Open Access
- 11 November 2025
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 25 (1) , 1-20
Explainable machine learning for differential diagnosis of diabetic foot infection and osteomyelitis: a two-center study and clinically applicable web calculator using routine blood biomarkers
Diabetic foot complications, including infections and osteomyelitis, pose significant health risks, with high prevalence and amputation rates. Differentiating diabetic foot infection (DFI) from osteomyelitis (OM) is challenging due to overlapping symptoms and limitations of current diagnostic methods. This study aimed to develop and validate an explainable machine learning (ML) model using routine blood biomarkers to improve differential diagnosis and provide a clinically accessible tool. This retrospective, two-center study included 3,612 patients diagnosed with either DFI (n = 1,699) or OM (n = 1,913). Data from Center 1 (n = 3271) were used for model development (75% training, 25% internal validation), and data from Center 2 (n = 341) served as an independent external validation cohort. A robust feature selection pipeline identified the most predictive routine biomarkers. Multiple machine learning classifiers were trained and evaluated, with the top-performing model selected based on the area under the receiver operating characteristic curve (AUC), Brier score, and other key metrics. Explainable AI (XAI) techniques (SHAP, LIME) were used to ensure model transparency. A web-based calculator was developed for clinical translation. A LightGBM model using only six biomarkers—Age, HbA1c, Creatinine, Albumin, ESR, and Sodium—was selected as the final model. It achieved an AUC of 0.879 (95% CI 0.854–0.902) in internal validation and demonstrated excellent, generalizable performance in the external cohort with an AUC of 0.942 (95% CI 0.936–0.950). The model was well-calibrated and showed significant clinical utility in decision curve analysis. SHAP analysis quantified the specific contribution of each biomarker to individual predictions, enhancing interpretability. The final model was deployed as a user-friendly, publicly accessible web calculator. An externally validated machine learning model based on six routine blood biomarkers can accurately and reliably differentiate DFI from OM. The model demonstrated high discriminative performance and clinical utility. Deployed as a transparent web calculator with integrated explainable AI, this low-cost tool has the potential to aid clinicians in diagnostic decision-making, particularly in resource-limited settings. Not applicable.
- 11 November 2025
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 25 (1) , 1-20
Open AccessExplainable machine learning for differential diagnosis of diabetic foot infection and osteomyelitis: a two-center study and clinically applicable web calculator using routine blood biomarkers
Diabetic foot complications, including infections and osteomyelitis, pose significant health risks, with high prevalence and amputation rates. Differentiating diabetic foot infection (DFI) from osteomyelitis (OM) is challenging due to overlapping symptoms and limitations of current diagnostic methods. This study aimed to develop and validate an explainable machine learning (ML) model using routine blood biomarkers to improve differential diagnosis and provide a clinically accessible tool. This retrospective, two-center study included 3,612 patients diagnosed with either DFI (n = 1,699) or OM (n = 1,913). Data from Center 1 (n = 3271) were used for model development (75% training, 25% internal validation), and data from Center 2 (n = 341) served as an independent external validation cohort. A robust feature selection pipeline identified the most predictive routine biomarkers. Multiple machine learning classifiers were trained and evaluated, with the top-performing model selected based on the area under the receiver operating characteristic curve (AUC), Brier score, and other key metrics. Explainable AI (XAI) techniques (SHAP, LIME) were used to ensure model transparency. A web-based calculator was developed for clinical translation. A LightGBM model using only six biomarkers—Age, HbA1c, Creatinine, Albumin, ESR, and Sodium—was selected as the final model. It achieved an AUC of 0.879 (95% CI 0.854–0.902) in internal validation and demonstrated excellent, generalizable performance in the external cohort with an AUC of 0.942 (95% CI 0.936–0.950). The model was well-calibrated and showed significant clinical utility in decision curve analysis. SHAP analysis quantified the specific contribution of each biomarker to individual predictions, enhancing interpretability. The final model was deployed as a user-friendly, publicly accessible web calculator. An externally validated machine learning model based on six routine blood biomarkers can accurately and reliably differentiate DFI from OM. The model demonstrated high discriminative performance and clinical utility. Deployed as a transparent web calculator with integrated explainable AI, this low-cost tool has the potential to aid clinicians in diagnostic decision-making, particularly in resource-limited settings. Not applicable.